Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Cancer Res. 2013 Aug 8;73(19):6024–6035. doi: 10.1158/0008-5472.CAN-13-1198

Figure 2. LJM716 inhibits HER3 signaling in vivo and is efficacious in multiple ligand-dependent and independent xenograft tumor models.

Figure 2

(A) BT474 xenografts were dosed intravenously with a single 20 mg/kg dose of LJM716 and tumors were harvested at 0, 4 or 24 hours followed by analysis of lysates for pHER3 and pAKT levels by MSD assay.

(B) BxPC-3 xenografts were dosed intravenously with a single 20 mg/kg dose of LJM716 and tumors were harvested at 0, 4, or 72 hours followed by analysis of lysates for pHER3 and pAKT levels by MSD assay.

(C) BT474 xenografts were dosed intravenously every other day with 20 mg/kg LJM716 (red) or IgG (black).

(D) HBCx-13A primary human xenografts were dosed intravenously every other day with 20 mg/kg LJM716 (red) or IgG (black).

(E) BxPC-3 xenografts were dosed intravenously every other day with 20 mg/kg LJM716 (red) or IgG (black).

(F) FaDu xenografts were dosed intravenously every other day with 20 mg/kg LJM716 (red) or IgG (black).

Two-tailed non-paired t-test was performed for A+B. Data in C–F are presented as mean tumor volume ±SEM. All delta volumes subjected to One Way ANOVA and Tukeys post hoc analysis. * indicates p<0.05; ** indicates p<0.01; *** indicates p<0.001.